Expand DRTS Menu
DRTS MENU

DRTS Stock Posts


Unusual Option Volume

DRTS Alpha Tau Medical Ltd. -13.35-0.12 (-0.9%)

Alpha Tau Medical Ltd. - trades 2,741 contracts. The company has the following event: AHNS 12th International Conference on Head and Neck Cancer between Jul 18, 2026 and Jul 22, 2026. News: Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
View Details...
Unusual Option Volume

DRTS Alpha Tau Medical Ltd. -12.25+1.03 (+9.2%)

Alpha Tau Medical Ltd. - trades 3,089 contracts. The company has the following event: AHNS 12th International Conference on Head and Neck Cancer between Jul 18, 2026 and Jul 22, 2026.
View Details...
Unusual Option Volume

DRTS Alpha Tau Medical Ltd. -10.71+0.13 (+1.2%)

Alpha Tau Medical Ltd. - trades 2,431 contracts. The company has the following event: AHNS 12th International Conference on Head and Neck Cancer between Jul 18, 2026 and Jul 22, 2026.
View Details...
Unusual Option Volume

DRTS Alpha Tau Medical Ltd. -10.82+1.89 (+21.2%)

Alpha Tau Medical Ltd. - trades 4,685 contracts. The highest volume is in the 18-Jun-26 12.5 calls, which is 15.5% above the current price. News: Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients
View Details...
Unusual Option Volume

DRTS Alpha Tau Medical Ltd. -10.53+0.12 (+1.2%)

Alpha Tau Medical Ltd. - trades 2,406 contracts. The company has the following event: 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 21, 2026.
View Details...
Unusual Option Volume

DRTS Alpha Tau Medical Ltd. -10.16+1.65 (+19.4%)

Alpha Tau Medical Ltd. - trades 2,378 contracts. The company has the following event: Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma on May 11, 2026. News: Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
View Details...
Load Earlier Posts
Market Data Delayed 15 Minutes